Association of 25-hydroxyvitamin D levels and cutaneous melanoma: A nested case-control study of the Women's Health Initiative Observation Study - 18/06/18
Supported by the National Heart, Lung, and Blood Institute (National Clinical Trial identifier NCT00000611) and the American Skin Association Medical Student Grant. The Population Architecture Using Genomics and Epidemiology program is funded by the National Human Genome Research Institute, which is supported by grants U01HG004790, U01HG007376 (Women's Health Initiative), and U01HG004801 (Coordinating Center). |
|
Disclosure: Dr Manson receives funding from the National Institutes of Health (grant CA138962) to conduct the Vitamin D and OmegA-3 Trial (VITAL), a randomized trial of vitamin D and omega-3 fatty acid supplementation in the prevention of cancer and cardiovascular disease. Dr Chlebowski is a consultant for Pfizer, Novartis, Amgen, Genentech, Genomic Health, and Novo Nordisk, and he is on the speaker's bureau for Novartis and Genentech. Dr Clarke receives research support from Genentech outside the submitted work. Drs Kwon, Gamba, Stefanick, Swetter, Li, Shi, Feldman, Millen, Messina, Shikany, and Tang have no conflicts of interest to disclose. |
|
This work was presented in the Society for Investigational Dermatology in 2016. |
Vol 79 - N° 1
P. 145-147 - juillet 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?